Status:

COMPLETED

Study of an Intervention to Improve Use of Life-saving Medications for Heart Disease

Lead Sponsor:

Duke University

Collaborating Sponsors:

Pfizer

Agency for Healthcare Research and Quality (AHRQ)

Conditions:

Cardiovascular Disease

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

The purpose of this study is to evaluate the effectiveness of a program to help patients with heart disease stay on their heart medications.

Detailed Description

Heart disease is the leading cause of death for men and women in the United States. For patients with documented coronary artery disease (CAD), anti-platelet agents, beta-blockers and statins have all...

Eligibility Criteria

Inclusion

  • 18 years of age or older
  • Utilize a pharmacy in Durham, Robeson, Person, Granville, or Vance County, NC
  • Have coronary artery disease (CAD) documented in the medical record by one of the following:
  • A diagnosis of unstable angina or acute myocardial infarction (ST segment elevation or non-ST segment elevation myocardial infarction)
  • A cardiac catheterization demonstrating CAD greater than or equal to 50 narrowing of artery)
  • Prior angioplasty
  • Prior coronary artery stent
  • Prior coronary artery bypass graft surgery (CABG)
  • Plan to have their prescription medications filled and refilled by one of the participating pharmacies
  • Prescribed aspirin or another antiplatelet, a beta-blocker and statin agent (referred to as triple therapy for this study) at discharge. If a patient has a true contraindication to any of the three medication groups in triple therapy, they will still be eligible for the study

Exclusion

  • Providers predict an anticipated hospital stay of less than 48 hours
  • Patient plans to use a pharmacy outside of Durham, Robeson, Person, Granville, or Vance County, NC
  • Patient is unable to give consent (cognitively impaired, does not speak English, or has altered mental status)
  • Patient transferred to Cardiothoracic Surgery service for CABG
  • Patient has terminal condition and may not survive until 6-month follow-up
  • Patient lives in a correctional or long-term care facility
  • Patient will be unable to participate in follow-up phone call (hearing impaired without caregiver who can help or does not have a phone)
  • Patient is a known participant in the Duke Heart Failure Program
  • Patient does not agree to use only the one Durham, Robeson, Person, Granville, or Vance County pharmacy throughout the study period

Key Trial Info

Start Date :

June 1 2006

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

March 1 2011

Estimated Enrollment :

143 Patients enrolled

Trial Details

Trial ID

NCT00323258

Start Date

June 1 2006

End Date

March 1 2011

Last Update

January 18 2013

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Duke University Medical Center

Durham, North Carolina, United States, 27704

Study of an Intervention to Improve Use of Life-saving Medications for Heart Disease | DecenTrialz